SGN-LIV1A is an ADC that combines a humanized anti-LIV-1 monoclonal antibody linked to a synthetic cytotoxic (cell-killing) agent, monomethyl auristatin E (MMAE). The ADC is designed to bind to LIV-1 proteins, which are expressed in most subtypes of metastatic breast cancer, and to release the potent cytotoxic agent MMAE into the target cell upon internalization into LIV-1-expressing tumor cells. This approach is intended to spare non-targeted cells and may reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.


SGN-LIV1A is being evaluated in a phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave